A single CRISPR infusion cut LDL by ~45% in primates — and held for 3 years
mRNA and gene-editing research had a productive week — not in a vague, promising-future-ahead way, but in a concrete, numbers-on-the-board way.
From a one-shot cholesterol fix that lasted three years in primates to a PEG workaround that triples mRNA expression after repeat dosing, here's what actually moved the needle.
One shot, three years of lower cholesterol 🧬
- Researchers delivered a CRISPR adenine base editor — packaged in a GalNAc-lipid nanoparticle — that targets ANGPTL3, a gene that drives up LDL and triglycerides. A single infusion in nonhuman primates knocked circulating ANGPTL3 protein down by more than 90%, with effects confirmed out to three years post-dose.
- In hyperlipidemia animal models, LDL dropped roughly 40–50% and triglycerides fell 50–70%. Editing was liver-selective, and off-target analysis across ~3,000 candidate sites found no detectable edits or structural variants.
- The study has now seeded a first-in-human trial in patients with refractory hyperlipidemia syndromes.
Why it matters: Most cholesterol drugs require daily or monthly dosing forever. A single-course edit that holds for years — if it translates to humans — would fundamentally change how chronic cardiovascular risk is managed.
Key Findings
The PEG problem in repeat-dose mRNA vaccines has a fix — maybe 💉
- Antibodies can complicate repeat dosing. Researchers tested an alternative carrier in mice.
- The animal study found differences in how immune cells responded. Human studies would be needed to establish a clinical advantage.
mRNA delivered to the brain — including in a primate 🧠
- Researchers detected delivery to brain tissue in animal models, including a nonhuman primate.
- The investigators also reported reduced injury in a mouse model. The study provides preclinical evidence.
A gut-delivered mRNA therapy reshaped immune cells in human tissue 🔬
- Glucocorticoid-derived lipid nanoparticles (MP2 LNPs) delivered mRNA rectally in mice with colitis, showing 15-fold higher efficiency than the FDA-approved SM102 formulation. Treated mice had preserved colon length and reduced inflammatory signals.
- Crucially, the team tested MP2 LNPs in biopsies from actual IBD patients — and saw meaningful shifts in regulatory versus inflammatory T cell populations, a rare step toward human-relevant validation.
A universal flu vaccine candidate that actually covers decades of drift 🦠
- Self-amplifying mRNA vaccines encoding computationally engineered influenza H5 antigens — representing both major phylogenetic groups and multiple neuraminidase subtypes — generated broad protection in mice and ferrets against H5N1 strains spanning two decades of evolution.
- Compared to WHO candidate vaccine viruses, the computationally designed multivalent approach (DVX-panH5Nx) showed superior cross-clade protection, with efficacy at doses as low as 0.4 µg in influenza A models.
Frailty quietly undermines mRNA vaccine responses in older adults 👴
- A Lancet Healthy Longevity review examined COVID-19 mRNA vaccine data and found that frailty — through immunosenescence, chronic inflammation, and impaired innate and adaptive immune function — is associated with weaker and less durable vaccine responses compared to non-frail peers.
- The review argues that LNP composition, dosing, and mRNA cargo could all be tuned for frailty, but frailty-specific trial data remain scarce, making firm recommendations premature.
mRNA vaccines boosted T cell therapy against brain tumors in mice 🎯
- In glioblastoma mouse models, an mRNA vaccine encoding a tumor antigen drove expansion of adoptively transferred T cells to up to 80% of circulating CD8+ T cells — and improved tumor infiltration in the brain.
- The approach was extended to a human glioblastoma antigen (PTPRZ1), where mRNA-transfected dendritic cells combined with matched T cell therapy led to rejection of implanted primary human glioma cells expressing that antigen.
Implications
The through-line this week: delivery is no longer the bottleneck it was five years ago. Brain, gut, platelets, lymph nodes — mRNA is reaching them. The unresolved tension is durability: most expression windows are transient by design, and for chronic diseases, that means repeat dosing — which is exactly where anti-PEG immunity and immune tolerance start to complicate everything.
Studies in this issue
Primary sources used for this newsletter.
- Using Gene Editing in Living Organisms to Lower Blood Fat Levels by Targeting ANGPTL3main storyNature2026-11-06PMID 42994815
- Wide vaccine protection against different global influenza A/H5Nx virus strainskey findingCell reports. Medicine2026-11-05PMID 42987826
- Designing fat-based nanoparticles to deliver RNA medicines to the brainkey findingNature nanotechnology2026-11-03PMID 42977805
- Anti-inflammatory lipid nanoparticles allow targeted mRNA treatment for inflammatory bowel diseasekey findingNature communications2026-11-04PMID 42982860
- RNA Vaccines Increase and Activate T Cells in the Brain to Improve Cell Therapy for Glioblastomakey findingCancer research2026-11-04PMID 42981468
- How Frailty May Affect mRNA Vaccine Effectivenesskey findingThe lancet. Healthy longevity2026-11-03PMID 42976900
- Alternative Lipids Improve mRNA Treatment Effectiveness with Repeated Doses and Boost Delivery to Immune Cellskey findingACS nano2026-11-03PMID 42975285
Continue reading
All mRNA Technology issuesGet the next mRNA Technology issue
Seven papers, once a week. Free.